← Back to Clinical Trials
Recruiting NCT06019923

NCT06019923 Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06019923
Status Recruiting
Phase
Sponsor Women's Hospital School Of Medicine Zhejiang University
Condition Ovarian Cancer
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-10-26
Primary Completion 2026-09-10

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-10-26 with a primary completion date of 2026-09-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 75 years; * Pathological diagnosis of high-grade serous ovarian cancer; * Newly diagnosed ovarian cancer case without prior neoadjuvant therapy. Exclusion Criteria: * Non-primary (recurrent) patients; * Ovarian cancer patients who have not undergone surgical treatment; * Patients with a history of other malignancies.

Contact & Investigator

Central Contact

Hongyu Xie, phD

✉ xiehongyu@zju.edu.cn

📞 +86-15244773429

Principal Investigator

Hongyu Xie, phD

PRINCIPAL INVESTIGATOR

Women's Hospital School Of Medicine Zhejiang University

Frequently Asked Questions

Who can join the NCT06019923 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06019923 currently recruiting?

Yes, NCT06019923 is actively recruiting participants. Contact the research team at xiehongyu@zju.edu.cn for enrollment information.

Where is the NCT06019923 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT06019923 clinical trial?

NCT06019923 is sponsored by Women's Hospital School Of Medicine Zhejiang University. The principal investigator is Hongyu Xie, phD at Women's Hospital School Of Medicine Zhejiang University. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology